GoodRx pre-announces Q4 revenue above guidance; expects mid-single-digit growth in 2024

GoodRx Holdings, Inc.

2023-FY EPS reported -$0.02 revenue$750,265,000

Q4 2023 revenue and adjusted revenue expected $195-197M, up ~6-7% YoY and above prior guidance.
FY 2023 revenue expected $749-751M (-~2% YoY); adjusted revenue $759-761M (-~1% YoY).
Q4 outperformance driven by organic growth in Prescription Transactions, stronger respiratory season and favorable contracts.
Early 2024 outlook: Q1 and FY revenue and adjusted revenue to grow mid-single digits YoY; adjusted EBITDA margin in high-twenty% range.
Full Q4 and 2024 guidance to be provided on February earnings call.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GoodRx Holdings, Inc. updated its the fourth quarter and fiscal year ended December 31, 2023 guidance (reaffirmed).

Period: the fourth quarter and fiscal year ended December 31, 2023
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

GoodRx Holdings, Inc. (the “Company”) issued a press release announcing the Company’s preliminary estimates of certain financial results for the three months and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

GoodRx Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001809519-24-000006

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.